Resistance to the mTOR inhibitor everolimus is reversed by the downregulation of survivin in breast cancer cells.

Taglieri L, De Iuliis F, Giuffrida A, Giantulli S, Silvestri I, Scarpa S

DOI: 10.3892/ol.2017.6597
Published: 2017 Sep
Container: Oncology letters
Publisher: Not recorded
Open access: yes

Credibility signals

serious concern Score 10/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
serious concernRetraction Watch retraction: 1 retraction notice matched this DOI. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.3892/ol.2017.6597,
  title = {Resistance to the mTOR inhibitor everolimus is reversed by the downregulation of survivin in breast cancer cells.},
  author = {Taglieri L and De Iuliis F and Giuffrida A and Giantulli S and Silvestri I and Scarpa S},
  year = {2017},
  journal = {Oncology letters},
  doi = {10.3892/ol.2017.6597},
  url = {https://doi.org/10.3892/ol.2017.6597}
}

RIS

TY  - JOUR
TI  - Resistance to the mTOR inhibitor everolimus is reversed by the downregulation of survivin in breast cancer cells.
AU  - Taglieri L
AU  - De Iuliis F
AU  - Giuffrida A
AU  - Giantulli S
AU  - Silvestri I
AU  - Scarpa S
PY  - 2017
JO  - Oncology letters
DO  - 10.3892/ol.2017.6597
UR  - https://doi.org/10.3892/ol.2017.6597
ER  -

APA

L, T., F, D. I., A, G., S, G., I, S., & S, S. (2017). Resistance to the mTOR inhibitor everolimus is reversed by the downregulation of survivin in breast cancer cells.. Oncology letters. https://doi.org/10.3892/ol.2017.6597

Source records

pubmed · retrieved 2026-09-25T02:49:51.436Z